Core Viewpoint - HeartTech Medical (02291) reported a significant increase in revenue and net profit for the six months ending June 30, 2025, indicating strong growth in its congenital heart disease occluder products and successful commercialization of new biodegradable devices [1] Financial Performance - Total revenue reached 330 million RMB, representing a year-on-year increase of 32.36% [1] - Net profit attributable to shareholders was 182 million RMB, up 29.81% year-on-year [1] - Basic earnings per share stood at 0.5249 RMB [1] Product Performance - Sales revenue from congenital heart disease occluders increased from 129 million RMB for the six months ending June 30, 2024, to 161 million RMB for the same period in 2025, accounting for 51.6% and 48.7% of total revenue, respectively [1] - The growth in sales revenue is attributed to steady growth in traditional metal occluder products and successful commercialization of the fourth-generation MemoSorb® biodegradable septal occluder and atrial septal defect occluder [1] - The company is focusing on product iteration and differentiation through biodegradable technology [1]

Core Viewpoint - The company reported a significant increase in revenue and net profit for the six months ending June 30, 2025, indicating strong growth in its operations within the cardiac medical device sector [1]. Financial Performance - Revenue increased by 32.4% year-on-year to RMB 330 million [1] - Net profit attributable to shareholders rose by 29.8% year-on-year to RMB 182 million [1] - Basic earnings per share were reported at RMB 0.5249 [1] - The board of directors did not recommend the payment of an interim dividend for the six months ending June 30, 2025 [1] Business Focus and Strategy - The company has over 20 years of experience in the development, production, and commercialization of cardiac medical intervention devices [1] - It is successfully implementing the biodegradability of medical devices and exploring advanced fields such as cardiac valves, mechanical circulatory support, and atrial septal puncture [1] - As a leader in China's interventional medical device industry, the company aims to provide safe, efficient, innovative, and comprehensive medical solutions [1] Product Portfolio - The company currently has 30 products in the market, including occluders, cardiac valves, and accessories [1] - There are 4 products undergoing registration review and preparation [1] - An additional 28 products are in various stages of research and development, including occluders, cardiac valves, surgical accessories, and mechanical circulatory support devices [1]

[Financial Highlights](index=1&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) During the reporting period, the company achieved significant growth in revenue, gross profit, R&D expenses, and net profit attributable to parent company shareholders, but the board does not recommend an interim dividend Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB million) | June 30, 2024 (RMB million) | Year-over-year growth rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 329.7 | 249.1 | 32.4 | | Gross Profit | 284.3 | 226.7 | 25.4 | | R&D Expenses | 25.4 | 21.7 | 17.0 | | Net Profit Attributable to Parent Company Shareholders | 182.0 | 140.2 | 29.8 | - The Board does not recommend an interim dividend for the six months ended June 30, 2025 (for the six months ended June 30, 2024: nil)[5](index=5&type=chunk) [Management Discussion and Analysis](index=2&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E8%88%87%E5%88%86%E6%9E%90) During the reporting period, the company maintained strong business momentum with stable revenue growth, continuous innovation in cardiovascular interventional devices, particularly in biodegradable technology and structural heart disease treatment, and active expansion in domestic and international markets [Business Review](index=2&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7) The company specializes in R&D, production, and commercialization of cardiovascular interventional devices, offering a broad product portfolio including congenital heart disease occluders, PFO and LAA occluders, heart valves, mechanical circulatory support, and access products, with many innovative products successfully commercialized or in clinical stages [Overall Operating Performance](index=5&type=section&id=%E6%95%B4%E9%AB%94%E7%B6%93%E7%87%9F%E6%A5%AD%E7%B8%BE) During the reporting period, the company achieved double-digit growth in revenue and net profit, significantly increased operating cash flow, and maintained steady growth in total assets Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB million) | June 30, 2024 (RMB million) | Year-over-year growth rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 329.7 | 249.1 | 32.4 | | Net Profit Attributable to Parent Company Shareholders | 182.0 | 140.2 | 29.8 | | Net Cash Generated from Operating Activities | 166.8 | 103.5 | 61.2 | | Total Assets (end of period) | 2,279.1 | 2,083.0 (beginning of reporting period) | 9.4 | | Net Assets (end of period) | 1,973.2 | 1,997.0 (beginning of reporting period) | -1.2 | [Congenital Heart Disease Occluder Products](index=2&type=section&id=%E5%85%88%E5%A4%A9%E6%80%A7%E5%BF%83%E8%87%9F%E7%97%85%E5%B0%81%E5%A0%B5%E5%99%A8%E7%94%A2%E5%93%81) The company maintains a leading position in congenital heart disease occluders, with third-generation oxide film and fourth-generation biodegradable occluder series successfully commercialized, becoming a cornerstone of business growth and embodying the "intervention without implant" philosophy - As of the date of this announcement, the Company has a total of **30** listed occluders, heart valve and accessory products, **4** products under registration review and preparation, and **28** pipeline products including occluders, heart valve and surgical accessories, and mechanical circulatory support at various R&D stages[6](index=6&type=chunk) - The fourth-generation MemoSorb® biodegradable atrial septal defect occluder product obtained the medical device registration certificate from the NMPA in August 2024 and has been rapidly commercialized[11](index=11&type=chunk) - Adhering to the technical concept of "intervention without implant," the Group will continue to promote the R&D and promotion of biodegradable materials[11](index=11&type=chunk) [PFO and LAA Occluder Products](index=6&type=section&id=%E5%8D%B5%E5%9C%93%E5%AD%94%E6%9C%AA%E9%96%89%E5%8F%8A%E5%B7%A6%E5%BF%83%E8%80%B3%E5%B0%81%E5%A0%B5%E5%99%A8%E7%94%A2%E5%93%81) First-generation cardiogenic stroke prevention products have been commercialized, with third-generation MemoSorb® biodegradable PFO occluders achieving over **RMB 200 million** in sales since launch, second-generation oxide film PFO occluders entering the registration application stage, and biodegradable LAA occluders entering multi-center clinical trials - The third-generation MemoSorb® biodegradable PFO occluder was approved for market in September 2023, with cumulative sales exceeding **RMB 200 million** as of June 30, 2025[12](index=12&type=chunk) - The second-generation oxide film PFO occluder has completed clinical follow-up and entered the registration application stage, with NMPA registration submission expected in **Q3 2025**[12](index=12&type=chunk) - The Bio-Lefort® biodegradable LAA occluder pipeline product has officially entered the multi-center clinical trial enrollment phase[12](index=12&type=chunk) [Aortic and Peripheral Occluder Devices](index=7&type=section&id=%E4%B8%BB%E5%8B%95%E8%84%88%E5%8F%8A%E5%A4%96%E5%91%A8%E5%B0%81%E5%A0%B5%E5%99%A8%E6%A2%B0) The company is strategically developing biodegradable aortic occluders and aortic embolization occluders in the aortic and peripheral fields, with both global innovative products having entered clinical trial stages, poised to address international challenges and offering promising market prospects - Both biodegradable aortic occluders and aortic embolization occluders have completed type testing and animal experiments, entering the clinical trial stage[13](index=13&type=chunk) - Currently, no targeted therapeutic devices for aortic dissection rupture and post-aortic aneurysm repair type II endoleak have been commercialized, making both of the Group's products global innovations[13](index=13&type=chunk) [Heart Valve Pipeline Products](index=7&type=section&id=%E5%BF%83%E8%87%9F%E7%93%A3%E8%86%9C%E5%9C%A8%E7%A0%94%E7%94%A2%E5%93%81) The ScienCrown® transcatheter aortic valve system was commercialized in early 2025, entering over **70** clinical centers in China, and the company is actively developing new products for aortic regurgitation, mitral valve repair, and replacement - The ScienCrown® transcatheter aortic valve system was officially commercialized in early 2025, having entered over **70** clinical centers in China for implantation[14](index=14&type=chunk) - A transcatheter aortic valve system for patients with isolated aortic regurgitation is currently under development, having completed animal experiments and type testing, with clinical trials planned for late 2025[14](index=14&type=chunk)[15](index=15&type=chunk) - The transapical mitral valve clip system is undergoing its second phase of clinical trials, with registration application to the NMPA expected to be postponed until 2026[15](index=15&type=chunk) [Mechanical Circulatory Support Products](index=8&type=section&id=%E6%A9%9F%E6%A2%B0%E5%BE%AA%E7%92%B0%E8%BC%94%E5%8A%A9%E7%94%A2%E5%93%81) The company has entered the mechanical circulatory support (MCS) device field, with a product line covering short-term and long-term ventricular assist systems, and multiple products in preclinical or type testing stages, aiming to become a core participant in this domain - The Company has entered the mechanical circulatory support (MCS) device field, with these devices designed to provide temporary or long-term support for patients requiring cardiac assistance[16](index=16&type=chunk) - The transcatheter left ventricular assist system for left ventricular support is in the preclinical type testing stage, with batch animal experiments already initiated[16](index=16&type=chunk) - The Company is one of the earliest pioneers in the domestic MCS field and is confident in becoming one of the most core and valuable participants in this area[16](index=16&type=chunk) [Access Products](index=8&type=section&id=%E9%80%9A%E8%B7%AF%E9%A1%9E%E7%94%A2%E5%93%81) The company boasts a rich pipeline of access products, with RF-Lance® radiofrequency puncture devices and needles approved for market, biodegradable LAA occluder delivery systems launched, and multiple valve surgery accessories (such as aortic valve balloon dilation catheters) approved or in clinical/registration stages - The RF-Lance® radiofrequency puncture device and RF-Lance® disposable radiofrequency atrial septal puncture needle were approved for market

Group 1 - The company, HeartTech Medical (02291.HK), announced that it will hold a board meeting on August 22, 2025, to consider and approve its unaudited interim results for the six months ending June 30, 2025 [1] - The board meeting will also discuss the potential declaration of an interim dividend, if applicable [1]

（股份代號：2291） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 樂普心泰醫療科技（上海）股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2025年8月22日（星期五）舉行董事會會議，藉以（其中包 括）考慮及批准本公司及其附屬公司截至2025年6月30日止六個月的未經審核中期 業績及其發佈，並考慮建議派發中期股息（如有）。 * 本公司註冊為香港法例第622章《公司條例》所定義的非香港公司，以其中文名稱及英文名 稱「LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.」註冊。 承董事會命 樂普心泰醫療科技（上海）股份有限公司 陳娟女士 董事長兼執行董事 中 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2 ...

Core Viewpoint - The stock of HeartTech Medical (2291.HK) experienced a significant increase, reaching a high of 27.4 HKD, marking a 30% rise over the past month, with a total market capitalization of 9.3 billion HKD [1] Company Summary - HeartTech Medical is recognized as a leading manufacturer of congenital heart disease occluders in China, holding a market share of 38% based on sales revenue in 2021 [1] - The company is characterized as a stable and profitable innovative medical device enterprise listed in Hong Kong [1] Industry Summary - The National Healthcare Security Administration has introduced a new pricing mechanism for newly launched drugs, adding over 100 price items related to new medical technologies to promote the clinical application of high-end medical devices [1] - According to CITIC Securities, the overall innovation capability of Hong Kong's medical device companies is strong, with many firms approaching profitability or experiencing rapid performance releases [1] - The medical device sector has seen significant stock price increases this year, with some companies doubling in value due to new product launches, technological breakthroughs, and strong cash positions [1]

Group 1 - The article provides a list of companies listed on the Hong Kong stock market along with their dividend distribution dates and shareholder meeting dates [1][4][5] - Notable companies mentioned include China Railway, Green Town China, and Budweiser APAC, which are scheduled for dividend payments [4][5] - The document outlines various companies' actions regarding capital increases and dividend distributions, indicating ongoing corporate activities in the market [4][5]

[Company Announcement: Proposed Appointment of Supervisor and Supplemental Announcement Regarding Annual Reports](index=1&type=section&id=%E5%85%AC%E5%8F%B8%E5%85%AC%E5%91%8A%EF%BC%9A%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B%E5%8F%8A%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) This announcement details the proposed appointment of a new supervisor and clarifies supervisor remuneration in annual reports [Proposed Appointment of Supervisor](index=1&type=section&id=%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B) The company proposes Ms. Wang Yong as shareholder representative supervisor and chairperson, pending shareholder approval - The company's board of supervisors recommends appointing Ms. Wang Yong as a supervisor and chairperson of the second board of supervisors[3](index=3&type=chunk) - This appointment is subject to approval by an ordinary resolution at the general meeting of shareholders[3](index=3&type=chunk)[8](index=8&type=chunk) - As a shareholder representative supervisor, Ms. Wang will not receive any remuneration from the company[7](index=7&type=chunk) [Supervisor Candidate Background: Ms. Wang Yong](index=1&type=section&id=%E7%9B%A3%E4%BA%8B%E5%80%99%E9%81%B8%E4%BA%BA%E7%9A%84%E8%83%8C%E6%99%AF) Ms. Wang Yong, 52, CFO of Lepu Medical, possesses CPA qualifications and audit experience Key Background Information | Item | Content | | :--- | :--- | | Age | 52 | | Nationality | China | | Current Key Positions | CFO, Senior Deputy General Manager at Lepu Medical (Controlling Shareholder, 300003.SZ) | | Past Key Experience | Senior Audit Manager, Audit Department, PwC Zhong Tian CPAs Beijing Branch (1996-2007) | | Professional Qualifications | Certified Public Accountant (obtained 2001) | Shareholding Information | Company Held | Capacity | Shares/Percentage | | :--- | :--- | :--- | | The Company | Via Employee Stock Ownership Platform | 147,221 shares (approx. 0.04%) | | Lepu Medical | Beneficial Owner | 191,700 shares (approx. 0.01%) | | Beijing Lepu Diagnostics | Via Employee Stock Ownership Platform | 383,955 shares (approx. 0.10%) | - Ms. Wang holds director or supervisor positions in several affiliated or non-affiliated companies, including Sichuan Ruijian Medical, Shanghai Lepu Yunzhi, and Sino-American Huashitong[4](index=4&type=chunk) [Supplemental Announcement Regarding Annual Reports](index=3&type=section&id=%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) The company clarifies that total remuneration paid to all supervisors for fiscal years 2022-2024 was zero - This announcement provides supplementary information for the company's 2022, 2023, and 2024 annual reports[9](index=9&type=chunk) Total Remuneration Paid to All Supervisors | Fiscal Year | Total Remuneration Paid to All Supervisors | | :--- | :--- | | 2022 | Zero | | 2023 | Zero | | 2024 | Zero | - The disclosed total remuneration of zero covers all items, including fees, basic salary, housing allowances, in-kind benefits, and bonuses[9](index=9&type=chunk)

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]